Scientists Resurrect Ancient Cannabis Enzymes in Biotech Breakthrough

Millions of Years of Evolution, Decoded in a Lab

A team of researchers at Wageningen University & Research in the Netherlands has accomplished something that sounds like it belongs in a science fiction novel: they have resurrected extinct enzymes from cannabis ancestors that lived millions of years ago and used them to produce cannabinoids in yeast cells. The study, published in Plant Biotechnology Journal, represents one of the most significant advances in cannabinoid biosynthesis research in years and could fundamentally change how the pharmaceutical and wellness industries produce THC, CBD, and especially rare cannabinoids like CBC.

The research addresses a problem that has vexed the cannabis biotech industry for over a decade. While scientists have long understood that cannabis produces cannabinoids through a series of enzymatic reactions, producing those same compounds in microorganisms like yeast has proven technically challenging. The modern enzymes responsible for cannabinoid production in cannabis plants are highly specialized and often difficult to express in non-plant systems. The Wageningen team's insight was to look backward — to reconstruct the ancestral forms of these enzymes that existed before millions of years of evolutionary specialization made them finicky.

How Ancestral Sequence Reconstruction Works

The technique the researchers used is called ancestral sequence reconstruction, a method borrowed from evolutionary biology. The approach starts with the DNA sequences of modern enzymes across related plant species and works backward through the evolutionary tree, using computational models to infer what the enzyme sequences looked like at various points in the past. Once the ancestral sequences are predicted, the researchers synthesize the corresponding DNA and express the resulting proteins in living organisms to see how they function.

In this case, the team reconstructed enzymes from cannabis ancestors that predated the plant's evolution into the distinct chemotypes we know today — the varieties that produce primarily THC, primarily CBD, or a mix of both. What they found was striking: the ancestral enzymes were generalists. Rather than producing just one cannabinoid, these ancient proteins could produce multiple cannabinoids simultaneously, including THC, CBD, and CBC. Over evolutionary time, gene duplications and subsequent mutations gradually specialized each enzyme copy, eventually producing the dedicated THC synthase and CBD synthase found in modern cannabis varieties.

Why Ancient Enzymes Are Better for Biotech

The most commercially significant finding was that these reconstructed ancestral enzymes proved to be more robust and more flexible than their modern descendants. According to researcher Robin van Velzen, the ancestral enzymes are "more robust and flexible than their descendants," making them significantly easier to produce in microorganisms like yeast.

This matters enormously for industrial cannabinoid production. The current state of the art in biosynthetic cannabinoid manufacturing involves inserting modern cannabis enzyme genes into yeast or bacteria and coaxing those microorganisms to produce cannabinoids through fermentation. The process works in principle, but yields have been limited by the difficulty of expressing highly specialized plant enzymes in microbial hosts. If ancestral enzymes are genuinely easier to work with in yeast — more stable, more productive, and less prone to misfolding — the economics of biosynthetic cannabinoid production could shift dramatically.

Several biotech companies are already pursuing yeast-based cannabinoid production, including firms like Demetrix (now part of Antheia) and Hyasynth Biologicals. These companies have achieved proof-of-concept results but have struggled to reach the yields necessary for cost-competitive commercial production. The Wageningen findings offer a potential path around the technical bottleneck by providing enzyme variants that are inherently better suited to microbial expression systems.

The CBC Opportunity

One of the most exciting aspects of the research is what it reveals about cannabichromene, or CBC. Among the major cannabinoids, CBC is perhaps the least studied but increasingly recognized for its therapeutic potential. Research has linked CBC to anti-inflammatory, analgesic, and antidepressant properties, and early studies suggest it may play a role in neurogenesis — the growth of new brain cells.

The problem with CBC is supply. Unlike THC and CBD, which can be extracted in large quantities from purpose-bred cannabis varieties, there is no cannabis plant with a naturally high CBC content. This has made CBC prohibitively expensive for research and commercial applications, leaving it largely unexplored compared to its more abundant cousins.

The Wageningen team identified one reconstructed ancestral enzyme that specifically produces CBC at meaningful yields. This finding opens the door to creating either new medicinal cannabis varieties — by introducing the ancestral CBC synthase into existing cultivars — or producing CBC at scale through microbial fermentation. Either path would dramatically increase the availability of CBC for research and product development, potentially unlocking an entirely new category of cannabinoid-based therapeutics.

Implications for the Cannabis Industry

The industrial implications of this research extend across multiple segments of the cannabis market. For pharmaceutical companies, biosynthetic cannabinoid production offers the holy grail of drug development: pure, consistent, pharmaceutical-grade compounds produced without the variability inherent in plant-based extraction. If ancestral enzymes can boost yeast-based production yields to commercially viable levels, the cost of cannabinoid active pharmaceutical ingredients could drop substantially.

For the wellness and consumer products sector, cheaper biosynthetic cannabinoids could accelerate the mainstreaming of minor cannabinoids like CBC, CBG, and CBN into everyday products. Currently, these compounds are expensive because they occur at low concentrations in cannabis plants and require costly purification processes. Yeast-based production could make them as affordable and accessible as CBD has become.

For cannabis cultivators, the implications are more nuanced. Biosynthetic production is not likely to replace the cannabis flower market — consumers buy flower for the full spectrum experience, including terpenes, flavonoids, and the ritualistic aspects of consumption. But for the industrial cannabinoid market that supplies ingredients to edibles, topicals, beverages, and pharmaceutical manufacturers, biotech production represents a serious competitive threat to traditional extraction-based supply chains.

The Broader Scientific Significance

Beyond its commercial applications, the Wageningen research contributes to a deeper understanding of how cannabis evolved its signature chemistry. The finding that ancestral enzymes were generalists that gradually specialized through gene duplication is consistent with a well-established model of enzyme evolution, but seeing it demonstrated experimentally in cannabis adds important detail to the story of how this plant became one of the most chemically diverse organisms in the plant kingdom.

The research also validates ancestral sequence reconstruction as a practical tool for industrial biotechnology, not just an academic exercise. By reaching into the evolutionary past and pulling out enzyme variants that are functionally superior for modern manufacturing purposes, the Wageningen team has demonstrated a methodology that could be applied to other plant-derived compounds facing similar production bottlenecks.

The study's lead author, Cloé Villard, and colleagues published their findings with full experimental data, providing the scientific community with the reconstructed sequences needed to replicate and extend the work. This openness is expected to accelerate follow-up research and attract attention from both academic labs and commercial biotech firms looking for competitive advantages in the growing cannabinoid production space.

What Comes Next

The path from a published paper to commercial application is never short, but the Wageningen results provide a clear roadmap. The immediate next steps involve optimizing the ancestral enzymes for maximal yield in industrial yeast strains, scaling up fermentation processes, and conducting the kind of rigorous quality testing required for pharmaceutical and consumer product applications.

For the cannabis industry as a whole, this research is a reminder that the most transformative innovations often come not from incremental improvements to existing methods but from fundamentally rethinking the approach. By looking backward through millions of years of evolution, the Wageningen team may have found the key to unlocking the next generation of cannabinoid production.

Key Takeaways

• Wageningen University researchers reconstructed extinct ancestral cannabis enzymes that produce THC, CBD, and CBC simultaneously.
• These ancient enzymes are easier to express in yeast than modern cannabis enzymes, potentially solving a key bottleneck in biosynthetic cannabinoid production.
• One ancestral enzyme specifically produces CBC, a rare cannabinoid with anti-inflammatory and neuroprotective properties that has been difficult to obtain at scale.
• The findings could reduce the cost of pharmaceutical-grade cannabinoids and accelerate the commercialization of minor cannabinoid products.

Explore cannabis news, find dispensaries, and join the community at Budpedia.